The Antibody Landscapes Following AS03 and MF59 Adjuvanted H5N1 Vaccination
2022 Aug 30
Journal Article
Authors:
Goll, J.B.;
Jain, A.;
Jensen, T.L.;
Assis, R.;
Nakajima, R.;
Jasinskas, A.;
Coughlan, L.;
Cherikh, S.R.;
Gelber, C.E.;
Khan, S.;
Davies, H.;
Meade, P.;
Stadlbauer, D.;
Strohmeier, S.;
Krammer, F.;
Chen, W.H.;
Felgner, P.L.
Secondary:
NPJ Vaccines
Volume:
7
Pagination:
103
Issue:
1
PMID:
36042229
URL:
https://pubmed.ncbi.nlm.nih.gov/36042229/
DOI:
10.1038/s41541-022-00524-7
Abstract:
Current seasonal and pre-pandemic influenza vaccines induce short-lived predominantly strain-specific and limited heterosubtypic responses. To better understand how vaccine adjuvants AS03 and MF59 may provide improved antibody responses to vaccination, we interrogated serum from subjects who received 2 doses of inactivated monovalent influenza A/Indonesia/05/2005 vaccine with or without AS03 or MF59 using hemagglutinin (HA) microarrays (NCT01317758 and NCT01317745). The arrays were designed to reflect both full-length and globular head HA derived from 17 influenza A subtypes (H1 to H16 and H18) and influenza B strains. We observed significantly increased strain-specific and broad homo- and heterosubtypic antibody responses with both AS03 and MF59 adjuvanted vaccination with AS03 achieving a higher titer and breadth of IgG responses relative to MF59. The adjuvanted vaccine was also associated with the elicitation of stalk-directed antibody. We established good correlation of the array antibody responses to H5 antigens with standard HA inhibition and microneutralization titers.
